Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Nutrition and Food Science
  •  Pediatrics
  •  Nuclear Medicine
  •  Tuberculosis
  •  Cardiology
  •  Orthopedic Sugery
  •  Genetics
  •  Anatomy

Abstract

Citation: Ann Clin Case Rep. 2018;3(1):1539.DOI: 10.25107/2474-1655.1539

Preliminary Clinical Outcomes from the PEEK-on-Ceramic Simplify™ Disc FDA IDE Trial

Mark R Alvis, Greg Maislin, David G Maislin and Brendan T Keenan

Simplify Medical, USA
Biomedical Statistical Consulting, USA

*Correspondance to: Mark R Alvis 

 PDF  Full Text Research Article | Open Access

Abstract:

This study was performed to evaluate the preliminary clinical results for the Simplify™ Cervical Artificial Disc. We compared outcomes for the first 61 subjects to reach Month 12 follow-up in a prospective, multicenter, FDA IDE clinical trial with 61 propensity score matched historical control subjects who received conventional Anterior Cervical Discectomy and Fusion (ACDF) for single-level cervical degenerative disc disease. The outcome measures included the change from preoperative baseline to Month 12 in Neck Disability Index (NDI) and Visual Analog Scales (VAS) for neck and arm pain with missing follow-up determined by last observation carried forward. The null hypothesis that the Simplify 1-disc is inferior to ACDF (non-inferiority margin=8.4) was rejected at a 1-sided p<0.0001. The upper bound of the 1-sided 95% non-inferiority confidence interval was -7.44 which is much smaller than the non-inferiority margin of 8.4. Superiority was demonstrated with a 2-sided p=0.0004. The upper bound of the 2-sided 95% confidence interval was -6.26 which is much less than zero. Sensitivity analyses on the assumptions about missing data and the matching included completer's analyses and analyses that were restricted to the 55 of 61 first stage matches that could be achieved without expanding of the calipers used to identify potential matches. The p-values for non-inferiority in all analyses are <0.0001. Similarly, the p-values for superiority are all ≤ 0.0030. Therefore, we conclude that the Simplify Disc is superior to ACDF control in terms of improvement in NDI and VAS from baseline to Month 12.

Keywords:

Cite the Article:

Alvis MR, Maislin G, Maislin DG, Keenan BT. Preliminary Clinical Outcomes from the PEEK-on-Ceramic Simplify™ Disc FDA IDE Trial. Ann Clin Case Rep. 2018; 3: 1539.

Search Our Journal

Journal Indexed In

Articles in PubMed

Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and Naturally Occurring Compounds, Part II
 PubMed  PMC  PDF  Full Text
Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Clinical Treatment and Observation of a Case of IgG4- Related Nephropathy Combined with Tuberculosis Infection
 Abstract  PDF  Full Text
Health Impact on the Elderly Survivors of COVID-19
 Abstract  PDF  Full Text
View More...